Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Olaparib
DRUG: Niraparib

Sponsor

Imunon